从港股行业表现来看，今年1月1日至7月29日，申万31个一级行业全部上涨，其中涨幅超过20%的行业 24个，涨幅超过40%的行业15个，涨幅超过60%的行业6个，涨幅前三大行业分别为农林牧渔、轻工制 造、医药生物，涨幅分别达174.98%、147.57%、103.13%；涨幅居后三大行业分别为家用电器、建筑装 饰，煤炭，涨幅分别为7.53%、9.52%、10.58%。 【深圳商报讯】（记者钟国斌）今年以来，港股领涨全球主要股市。DeepSeek、新消费、创新药等板 块轮番表现，助推港股恒生指数频创年内新高。据记者统计，截至今年7月29日，恒生指数收报 25524.45点，涨幅达27.24%，在全球主要股市涨幅第一。 从全球主要股市表现来看，今年以来港股市场一枝独秀。以美股、欧洲股市和日本股市为例，今年以 来，美国股市三大指数涨幅均为个位数，其中道琼斯指数涨幅为5.39%、标普500指数涨幅为8.64%，纳 斯达克指数涨幅为9.67%；德国、英国、法国股市涨幅分别为21.74%、11.53%、6.80%；日本股市日经 225指数涨幅为1.96%。 （文章来源：深圳商报） 从港股个股表现来看，今年1月1日至7月2 ...

写在文章前的声明：在本文之前的说明：本文中所列的投资信息，只是一个对基金资产净值进行排行的客观描述，并无主观倾向性，也不是投资建议，纯属 娱乐性质。 领涨概念：CXO概念、创新药、减肥药、仿制药、免疫治疗、EDA概念、CPO概念涨幅逾4%。 领跌行业：保险、农林牧渔。 | 排名 | 代码 | 基金简称 | 2025-07-29 | | 2025-07-28 | | Hall Sc | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 車位净值8 | 累计净值$ | 单位净值8 | 累计净值8 | | | 1 | 006430 | 凯石澜龙头经济持有期混合 | 0.8917 | 1.6117 | 0.8346 | 1.5546 | 0.05 | | 2 | 011412 | 易方达远见成长混合C | 1.4700 | 1.4700 | 1.3801 | 1.3801 | 0.08 | | 3 | 010115 | 易万达远见成长混合A | 1.4962 | 1.4962 | 1.4047 | 1.4047 | 0.09 | | 4 | 01189 ...

Market Performance - On July 29, 2025, the Shanghai Composite Index rose by 0.33%, the Shenzhen Component Index increased by 0.64%, and the ChiNext Index surged by 1.86%[2] - The total market turnover reached 17,894.23 billion CNY, an increase of 639.08 billion CNY compared to the previous trading day[2] - A total of 2,182 stocks rose while 2,863 stocks fell across the market[2] Sector and Style Analysis - The top-performing sectors included Communication (3.31%), Steel (2.31%), and Pharmaceuticals (1.97%), while Agriculture, Forestry, Animal Husbandry, and Fishery (-1.31%), Banking (-1.18%), and Home Appliances (-0.75%) lagged behind[21] - Growth stocks outperformed value stocks, with large-cap growth leading the performance[21] Capital Flow - On July 29, 2025, the net outflow of main funds was 356.48 billion CNY, with large orders contributing to the outflow of 196.48 billion CNY and 160.00 billion CNY respectively[25] - Small orders saw a continuous net inflow of 388.78 billion CNY[25] ETF Trading Activity - Major ETFs such as the Huaxia SSE 50 ETF and the Huatai-PB CSI 300 ETF saw varied trading volumes, with the former at 15.26 billion CNY (down 2.57 billion CNY) and the latter at 33.96 billion CNY (up 8.60 billion CNY)[29] - The main inflow was observed in the Sci-Tech 50 ETF, which attracted 12.15 billion CNY on July 28[29] Global Market Overview - On July 29, 2025, major Asia-Pacific indices showed mixed results, with the Hang Seng Index down 0.15% and the Nikkei 225 down 0.79%[32] - European indices generally declined, with the DAX down 1.02% and the FTSE 100 down 0.43%[33]

Group 1 - The core viewpoint of the article highlights the strategic moves by Huajian Medical, including the successful fundraising of a multi-billion RMB sustainable development-linked revolving loan and the launch of a Web3 exchange ecosystem for medical innovation drugs [1][2][3] - The revolving loan, led by East Asia Bank and supported by several international financial institutions, provides Huajian Medical with a flexible and ample medium to long-term funding pool, enhancing its capital structure and enabling it to seize industry growth opportunities [2][3] - Huajian Medical's stock price surged by 75% from July 14 to July 21, reaching a historical peak of 4.66 HKD, reflecting strong market sentiment and confidence in the company's future prospects [1][3] Group 2 - The management's decision to repurchase shares at high prices, following the stock's peak, signals confidence in the company's strategic direction and future growth [4][5] - The company has initiated a plan to establish a Web3 exchange named "IVDNewCo Exchange," which aims to integrate medical innovation drug assets with blockchain technology, potentially revolutionizing traditional pharmaceutical financing [5][6] - The proposed ecosystem includes a tokenization platform for real-world assets (RWA), a decentralized exchange for 24/7 global trading, and a stablecoin (IVDD) for transactions within the ecosystem [6][8] Group 3 - The global RWA market is projected to grow significantly, reaching 16.1 trillion USD by 2030, indicating a favorable environment for Huajian Medical's tokenization strategy [8][9] - The stablecoin market is also expanding, with a total market cap of 263.6 billion USD, suggesting a growing acceptance of new financial infrastructures [8][9] - Regulatory developments, such as the upcoming Hong Kong Stablecoin Regulation, are expected to facilitate Huajian Medical's initiatives in the Web3 space, enhancing investor confidence [8][9]

Group 1 - The article highlights the importance of weekly announcements from Sunday to Thursday, which include significant stock market updates such as suspensions, increases or decreases in holdings, investment wins, acquisitions, performance reports, unlocks, and high transfers [1] - Key sectors mentioned include PCB, PET copper foil, solid-state batteries, storage chips, and new energy vehicles, with a specific company involved in NVIDIA projects and 400G/800G optical module fields [1] - Another company is noted for its strategic cooperation framework agreement related to humanoid robots, solid-state batteries, computing power, and AI chips [1] Group 2 - The article discusses a company with 24 key products across 28 indications entering clinical stages, including 9 first-class innovative drugs in the fields of innovative drugs, biological vaccines, traditional Chinese medicine, and medical aesthetics [1]

7月29日，市场全天震荡走高，创业板指领涨。沪深两市全天成交额1.8万亿，较上个交易日放量609 亿。医药股集体大涨，CRO、创新药方向领涨，辰欣药业等多股涨停。CPO等算力硬件股震荡走强，中 际旭创等多股再创历史新高。截至收盘，沪指涨0.33%，深成指涨0.64%，创业板指涨1.86%。 ...

Core Viewpoint - The pharmaceutical sector has shown significant divergence in performance, with innovative drugs outperforming while other segments like medical devices and traditional Chinese medicine lag behind [1][2][3] Group 1: Performance Disparity - As of July 28, the performance gap among pharmaceutical theme funds exceeded 120%, with funds focused on Hong Kong innovative drugs leading the pack [1][2] - The China Securities Index for Hong Kong innovative drugs recorded a year-to-date increase of 111.08%, while the medical index only rose by 14.74% [2][3] - A total of 393 pharmaceutical-related funds were tracked, with the highest fund showing a net value increase of over 120% and the lowest at -3.08% [3] Group 2: Market Trends - The A-share pharmaceutical stocks continued to rise, with CRO concept stocks leading the gains, and multiple stocks increasing over 5% [2] - Hong Kong's biotechnology and healthcare indices also performed well, with increases of 4.11% and 3.82% respectively [2] - Despite the overall strong performance, there is a clear divide between the booming innovative drug sector and the underperforming medical and traditional Chinese medicine sectors [2][3] Group 3: Investment Strategies - Some fund managers have reduced their holdings in high-performing sectors like innovative drugs, opting for a balanced approach across medical devices and consumer healthcare [4] - The focus on defensive positions and dividend stocks has been noted as a reason for underperformance in certain funds [3][4] - Analysts suggest that while innovative drugs are currently strong, there are opportunities for valuation recovery in medical devices and healthcare sectors [6][7] Group 4: Risks and Future Outlook - The innovative drug sector's recent surge is attributed to favorable policies, successful international business development, and improved fundamentals [6] - However, there are accumulating short-term risks, including high trading congestion and potential regulatory hurdles [6] - Analysts from CITIC Construction Investment predict a recovery in the medical device sector's overall valuation, with several companies expected to turn profitable by 2025-2027 [7]

Core Insights - The company, Baiotai Biopharmaceutical Co., Ltd., reported a significant reduction in losses for the first half of 2025, with expected net losses between 1.1 billion to 1.4 billion yuan, a decrease of 970 million to 1.27 billion yuan compared to the same period last year [2] - The sales of the company's first approved biosimilar, Adalimumab Injection (brand name: Geleli®), have contributed to an increase in operating revenue by 20 million to 50 million yuan year-on-year, showcasing the effectiveness of the company's commercialization team [2] - Research and development expenses decreased by 40 million to 70 million yuan during the reporting period, indicating improved cost structure and efficiency [2] Financial Performance - The expected net profit for the first half of 2025 is projected to be between -1.1 billion to -1.4 billion yuan, reflecting a significant narrowing of losses compared to the previous year [2] - The increase in operating revenue is attributed to the successful commercialization of core products, particularly the sales growth of the Adalimumab Injection [2] R&D and Market Strategy - The company has achieved a milestone with the FDA approval of BAT2206, which is crucial for its international strategy [2] - BAT2306 and BAT2506 are currently in the application stage for market approval, indicating a robust pipeline for future growth [2] - The dual focus on biosimilars and innovative drugs is expected to provide strong momentum for the company's long-term development [2]

Group 1 - The first data point indicates a high level of market speculation, with net financing purchases reaching 19.2 billion, the second highest this year, only behind February 5 [2][3] - The financing balance has increased to 1.95 trillion, surpassing the previous high of 1.94 trillion in March, marking the second highest level in history, only below the bull market period of 2015 [2][3] - The current financing balance is described as the second most active in history, suggesting a significant level of market engagement [3] Group 2 - The second data point reflects the true economic temperature, with state-owned enterprises reporting a 0.2% decline in total revenue and a 3.1% decline in total profit for the first half of the year [10][11] - A survey by the central bank indicates a decline in income confidence and employment perception, with nearly 40% of respondents feeling the job market is "average" and over 53% perceiving it as "severe" or "uncertain" [10][11] Group 3 - The third data point explains the rationale behind the stock market's performance, highlighting that the current low interest rate environment in China is driving a structural market rally, leading to a revaluation of equity assets [12][13] - The average annualized return of financial products in the first half of the year is reported at 2.12%, down from 2.65% the previous year, indicating a decline in the overall risk-free interest rate [14][15] - Companies maintaining double-digit profit growth in a low-risk interest rate environment are seen as attractive investment opportunities, particularly in sectors like innovative pharmaceuticals [15][16] Group 4 - The innovative pharmaceutical sector has seen significant gains, with stocks rising nearly 100% this year, driven by recent agreements and market interest [19][21] - Reports indicate that leading innovative pharmaceutical companies have a price-to-sales ratio in line with historical averages, suggesting continued growth potential despite recent price increases [22][23] - Fund managers specializing in pharmaceuticals are optimistic about the sector's future, emphasizing the importance of stock selection in the current market environment [24]

机构投研需求呈现分化，部分券商分析师称需求增多、市场情绪旺盛，也有券商分析师认为，与此前变 化不大，且传统领域人气回升不明显。 此外，在"牛市"氛围渐浓的情况下，券商分析师"转会"依旧频繁，但仍以业内横向流动为主。同时，券 商分析师研究业务趋向多元化，保险资管等新领域，有望成为分析师转型的新方向。 "牛市"相关研报增多 近日，沪指在时隔9个月后首次突破3600点，"牛市"氛围逐渐成为A股市场的主流叙事，市场预测的目 标点位不断抬升。那么，作为行情风向标，券商研究所最近发布报告、举行路演、开电话会、开展调研 的频次，是不是也出现"水涨船高"的情况？ 慧博智能终端的数据显示，最近一周，券商研究所总共发布了各类投资策略研报近224份，研报数量较 此前没有明显增多。 近期，随着A股"牛市"氛围渐浓，券商相关"牛市"研报数量显著增加。 《每日经济新闻》记者了解到，近一个月，标题含"牛市"的券商策略报告达到13篇，占近3个月券商策 略报告总数量的57%。与此同时，7月以来，以"牛市"为关键词的电话会有17场，数量创下年内新高。 也有一些卖方分析师认为，最近，机构投研需求和之前变化不大。一家大型券商的策略首席分析师向 《每 ...